PetVivo Holdings Inc. (OTC: PETV) is a biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics, according to the company’s website; see here – www.PetVivo.com. SNNLive caught up with John Lai, CEO of PetVivo Holdings, Inc. at the Marcum MicroCap Conference 2015 in New York City, NY.
Mr. Lai begins the interview with an overview of the company, “PetVivo is primarily focused on treating animals with osteoarthritis, specifically, horses and dogs, and eventually we’ll roll into humans probably in year 3.” He goes on to discuss what differentiates PetVivo’s formulation from the competition.
We last interviewed John in April 2015 (see here: Update with PetVivo Holdings, Inc. - Pet Therapeutics Company Discusses Recent Acquisition of Gel-Del Technologies). In this interview he provides an update about what’s going on with PetVivo, “Well, we’re pretty excited – we’re finally closed on the acquisition of Gel-Del Technologies. It’s the side that has…35 patents and 17 products in the pipeline, but on top of that now we have identified...regional sales reps that I wanted to bring in to help support our distributor base. Plus, we are focused on manufacturing now; identifying key manufacturers that will fulfill the syringes. We will always make the particles, ship them to the fulfillment company, and then they’ll fill a standard 2 or 4cc syringe.”
For more information about PetVivo Holdings, Inc., go to: www.PetVivo.com
© 2017 Stock News Now
Supported by Superior Web Solutions